Associated Papers
Unusual fundus lesion in mosaic neurofibromatosis type 2.
Berry MH et al.
Ophthalmic Genetics, 2025
Uncommon molecular alterations in follicular-derived thyroid carcinoma: A single institution study.
Alexiev BA et al.
Pathology, Research and Practice, 2024
A novel NF2 splicing mutant causes neurofibromatosis type 2 via liquid-liquid phase separation with large tumor suppressor and Hippo pathway.
Jia Z et al.
Iscience, 2022
Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.
Chapel DB et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2022
Early prediction of functional prognosis in neurofibromatosis type 2 patients based on genotype-phenotype correlation with targeted deep sequencing.
Teranishi Y et al.
Scientific Reports, 2022
Targeted deep sequencing of DNA from multiple tissue types improves the diagnostic rate and reveals a highly diverse phenotype of mosaic neurofibromatosis type 2.
Teranishi Y et al.
Journal of Medical Genetics, 2021
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
Quetel L et al.
Molecular Oncology, 2020
32083805 (PubMed )
Supplement: MOL2-14-1207-s005.xlsx › Table_S4
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
Goutagny S et al.
Journal of Neuro-oncology, 2015
Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis.
Wallace AJ et al.
Genetic Testing, 2004
Familial schwannomatosis: exclusion of the NF2 locus as the germline event.
MacCollin M et al.
Neurology, 2003
Detection of novel NF2 mutations by an RNA mismatch cleavage method.
Faudoa R et al.
Human Mutation, 2000
Select a paper to view details